AbCellera Biologics Inc.
ABCL· Nasdaq
Released Nov 8, 2022, after the close
10-Q filed Nov 8, 2022, 39 days after period end · 0001564590-22-037060
| Metric | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|
| Revenue | $101.38M | $5.51M | $9.36M |
| Net Income | $26.62M | -$21.38M | -$2.69M |
| EPS Diluted | $0.08 | -$0.08 | -$0.02 |
AbCellera Biologics Inc. · CIK 1703057 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.